We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

First-of-its-Kind Trial to Measure Ejection Fraction Severity Directly from AI-Enabled Remote ECG Wearable

By HospiMedica International staff writers
Posted on 26 Jul 2024

Echocardiograms are a standard diagnostic tool to measure ejection fraction but require a clinical setting for administration. More...

This can pose challenges such as scheduling delays, staffing shortages, accessibility issues, and higher costs. A groundbreaking remote monitoring platform now offers a cost-effective alternative for measuring ejection fraction while minimizing patient inconvenience and enabling more regular assessments.

Developed by Peerbridge Health (New York, NY, USA), this innovative wearable ECG device is designed to deliver hospital-grade cardiac diagnostics and monitoring directly to patients' homes. The platform named Peerbridge Cor is an AI-powered device equipped with a three-lead, patented ambulatory electrocardiogram (AECG) wearable that utilizes a design derived from the Einthoven Triangle. This system uses ECG for diagnosing and monitoring critical cardiac functions more affordably than traditional methods. The data it collects offers actionable insights that can lead to early interventions, reduce hospital visits, and save lives.

Peerbridge Health has recently initiated the Ejection Fraction AI-enabled Clinical Trial (EF-ACT) to evaluate Left Ventricular Ejection Fraction (LVEF) severity directly from its Peerbridge Cor wearable ECG device. This pivotal trial aims to facilitate immediate evaluations of EF Severity based on the American Society of Echocardiography scale, usable both in clinical settings and at home. Ejection Fraction Severity categories are crucial for clinicians to determine the extent of heart dysfunction, which aids in making informed treatment and prognosis decisions. The trial, set to involve around 1,000 patients across various centers, follows a successful feasibility study conducted in 2023.

"This is the first pivotal trial to study direct-from-ECG ejection fraction (EF) severity at this level of fidelity," said Peerbridge Health CEO and President Chris Darland. "The findings of this trial could have a profound effect on access and affordability of cardiac care."

Related Links:
Peerbridge Health


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Desk Aneroid Sphyg
Diagnostix 750D+
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.